You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物-B(09926.HK):AK119用於治療COVID-19的臨試在新西蘭完成首例健康受試者給藥
格隆匯 10-27 06:20

格隆匯 10 月 27日丨康方生物-B(09926.HK)發佈公告,其自主研發的創新藥物CD73單克隆抗體(研發代號:AK119)在新西蘭的臨牀試驗完成首例健康受試者給藥,AK119擬用於治療新型冠狀病毒(“COVID-19”)患者。

此外,目前AK119在美國用於治療輕中度COVID-19患者的臨牀試驗已經獲得美國食品藥品監督管理局(FDA)的反饋,其同意公司遞交新藥臨牀試驗申請。

AK119為人源化單克隆抗體藥物,可顯着地抑制CD73的酶學活性。AK119可有效地引起B細胞活化並加強抗體產生。臨牀前數據顯示,AK119可通過不同於抑制CD73酶活性的途徑,上調B細胞活化的兩個早期標記分子(CD69和CD83)的表達,還可促進B細胞產生免疫球蛋白M(IgM)和免疫球蛋白G(IgG)抗體。COVID-19患者增加抗體產生或可會加強彼等消除SARS-CoV-2病毒的能力。因此,AK119或會是治療COVID-19疾病的有效方法。AK119亦可能使人體對SARS-CoV-2病毒產生更強的免疫力,並可能與健康人士接種的疫苗結合使用,以增強疫苗的效力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account